What is Artelo Biosciences Cash Flow from Investing?
Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).
For the
three
months ended in Dec. 2024, Artelo Biosciencesspent$0.00 Mil on purchasing property, plant, equipment.
It gained$0.00 Mil from selling property, plant, and equipment.
It spent$0.00 Mil on purchasing business.
It gained$0.00 Mil from selling business.
It spent$0.00 Mil on purchasing investments.
It gained$0.50 Mil from selling investments.
It paid$0.00Mil for net Intangibles purchase and sale.
And it paid$0.00 Mil for other investing activities.
In all, Artelo Biosciencesgained$0.50 Mil on investment activities in financial market and operating subsidiaries for the
three
months ended in Dec. 2024.
Artelo Biosciences Cash Flow from Investing Historical Data
The historical data trend for Artelo Biosciences's Cash Flow from Investing can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Artelo Biosciences Cash Flow from Investing Calculation
Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).
If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).
Likewise, if a company buys another company for cash, this will reduce their cash position.
Artelo Biosciences's Cash Flow from Investing for the fiscal year that ended in Dec. 2024 is calculated as:
Cash Flow from Investing for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $7.77 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Artelo Biosciences (NAS:ARTL) Cash Flow from Investing Explanation
Artelo Biosciences's purchase of property, plant, equipment for the
three
months ended in Dec. 2024 was $0.00 Mil. It means Artelo Biosciences spent $0.00 Mil on purchasing property, plant, equipment.
In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.
In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:
"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."
Artelo Biosciences's sale of property, plant, equipment for the
three
months ended in Dec. 2024 was $0.00 Mil. It means Artelo Biosciences gained $0.00 Mil from selling property, plant, and equipment.
3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.
Artelo Biosciences's purchase of business for the
three
months ended in Dec. 2024 was $0.00 Mil. It means Artelo Biosciences spent $0.00 Mil on purchasing business.
4. Sale Of Business:
Sale of business indicates the amount gained from selling business.
Artelo Biosciences's sale of business for the
three
months ended in Dec. 2024 was $0.00 Mil. It means Artelo Biosciences gained $0.00 Mil from selling business.
5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.
Artelo Biosciences's purchase of investment for the
three
months ended in Dec. 2024 was $0.00 Mil. It means Artelo Biosciences spent {stock_data.stock.currency_symbol}}0.00 Mil on purchasing investments.
6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.
Artelo Biosciences's sale of investment for the
three
months ended in Dec. 2024 was $0.50 Mil. It means Artelo Biosciences gained $0.50 Mil from selling investments.
7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.
Artelo Biosciences's net Intangibles purchase and sale for the
three
months ended in Dec. 2024 was $0.00 Mil.
It means Artelo Biosciences paid $0.00 Mil for net Intangibles purchase and sale.
8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.
Artelo Biosciences's cash from discontinued investing activities for the
three
months ended in Dec. 2024 was 0.00 Mil.
It means Artelo Biosciences paid $0.00 Mil for discontinued investing activities.
9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.
Artelo Biosciences's cash from other investing activities for the
three
months ended in Dec. 2024 was $0.00 Mil.
It means Artelo Biosciences paid $0.00 Mil for other investing activities.
Artelo Biosciences Cash Flow from Investing Related Terms
Thank you for viewing the detailed overview of Artelo Biosciences's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ARTL has been successfully added to your 